Antitrust Drug Price-Fixing Action

In In re: Lorazepam & Clorazepate Antitrust Litig., No. 08-5044, an action claiming that defendants entered into exclusive licensing agreements enabling defendant to raise the prices the insurance companies paid for two prescription anti-anxiety medications, the court vacated judgment for plaintiff where plaintiffs’ self-funded customers were required to be counted as parties for diversity of citizenship purposes, and thus the district court needed to examine the issue of its own jurisdiction.

Related Resources

  • Read the DC Circuit’s Decision in In re: Lorazepam & Clorazepate Antitrust Litig., No. 08-5044

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Civil Rights

Block on Trump’s Asylum Ban Upheld by Supreme Court

Criminal

Judges Can Release Secret Grand Jury Records

Politicians Can’t Block Voters on Facebook, Court Rules